Trial Profile
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma; Squamous cell cancer; Uterine cancer
- Focus Therapeutic Use
- Acronyms EndoBARR
- 30 Aug 2023 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 28 Apr 2022 According to a Clovis Oncology media release, data from the study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.